This is a working overview of nootropic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Soon after inoculation, yeast begin to rapidly consume the available assimilable nitrogen with up to 46% of YAN being fully consumed by the onset of full fermentation. Because inorganic nitrogen, such as the ammonium salts in DAP, are toxic to yeast in high levels, it is never added during inoculation when the biomass of the newly re-hydrated yeast is low. Many winemakers split up the dosage of DAP with the first addition being made at the end of the lag phase when the yeast enter their period of exponential growth and alcoholic fermentation begins. In most must this is around 48 to 72 hours after inoculation. A second dosage is then often added around a third of the way through sugar fermentation and often before the sugar levels hit 12-10 Brix (6.5 to 5.5 Baumé, 48.3 to 40.0 Oechsle) because as the fermentation progresses yeast cells are no longer able to bring the nitrogen into the cell due to the increasing toxicity of ethanol surrounding the cells. This leaves the nitrogen unused and available for spoilage organisms that may come afterwards.
is the derivative in the direction y, normal to x, of the flow velocity component u that is oriented along the direction x. In case of a general 2‑D incompressibile flow in the plane x, y, the Newton constitutive equation become:
Activation of CD4+ T cells occurs through the simultaneous engagement of the T-cell receptor and a co-stimulatory molecule (like CD28, or ICOS) on the T cell by the major histocompatibility complex (MHCII) peptide and co-stimulatory molecules on the APC. Both are required for production of an effective immune response; in the absence of co-stimulation, T cell receptor signalling alone results in anergy. The signalling pathways downstream from co-stimulatory molecules usually engages the PI3K pathway generating PIP3 at the plasma membrane and recruiting PH domain containing signaling molecules like PDK1 that are essential for the activation of PKC-θ, and eventual IL-2 production. Optimal CD8+ T cell response relies on CD4+ signalling. CD4+ cells are useful in the initial antigenic activation of naive CD8 T cells, and sustaining memory CD8+ T cells in the aftermath of an acute infection. Therefore, activation of CD4+ T cells can be beneficial to the action of CD8+ T cells. The first signal is provided by binding of the T cell receptor to its cognate peptide presented on MHCII on an APC. MHCII is restricted to so-called professional antigen-presenting cells, like dendritic cells, B cells, and macrophages, to name a few. The peptides presented to CD8+ T cells by MHC class I molecules are 8–13 amino acids in length; the peptides presented to CD4+ cells by MHC class II molecules are longer, usually 12–25 amino acids in length, as the ends of the binding cleft of the MHC class II molecule are open.
Mexicans have a constitutional right to own firearms, but legal purchase is highly restricted. The most common weapons used by the cartels are the AR-15, M16, M4, AK-47, AKM and Type 56 assault rifles, which are not available for sale in civilian markets. Grenade launchers are known to have been used against Mexican security forces, while H&K G36s and M4 carbines with M203 grenade launchers have been confiscated. Some cartels, such as the Beltrán Leyva Cartel, use counterfeit M16s made with aftermarket parts. Cartels also use body armor, Kevlar helmets, improvised explosive devices, narco-submarines and unmanned aerial vehicles. Grenades and rocket launchers are often smuggled through the Guatemalan borders, as leftovers from past conflicts in Central America, notably the Salvadoran Civil War and the Nicaraguan Revolution. Some explosive weapons are also smuggled from the U.S. to Mexico or stolen from the Mexican military. The U.S. Drug Enforcement Administration (DEA) reports that the Mexican drug cartels operating today along the border are far more sophisticated and dangerous than any other organized criminal group in U.S. law enforcement history. Project Gunrunner was a United States Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) operation aimed at curbing firearms trafficking into Mexico.
Leonidas Zervas (Greek: Λεωνίδας Ζέρβας, pronounced [leoˈniðas ˈzervas]; 21 May 1902 – 10 July 1980) was a Greek organic chemist who made seminal contributions in peptide chemical synthesis. Together with his mentor Max Bergmann they laid the foundations for the field in 1932 with their major discovery, the Bergmann-Zervas carboxybenzoxy oligopeptide synthesis which remained unsurpassed in utility for the next two decades. The carboxybenzyl protecting group he discovered is often abbreviated Z in his honour. Throughout his life Zervas also served in many important posts, including President of the Academy of Athens or briefly Minister of Industry of Greece. He received numerous awards and honours during his life and posthumously, such as Foreign Member of the USSR Academy of Sciences or the first Max Bergmann golden medal.
Sources: en.wikipedia.org
== Adverse effects == In a systematic review analyzing data from 5 cohort studies having 1,085,488 patients, use of gabapentinoids (pregabalin and gabapentin) was associated with an increased risks of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids. Exposure to pregabalin is associated with weight gain, drowsiness, fatigue, dizziness, vertigo, leg swelling, disturbed vision, loss of coordination, and euphoria. It has an adverse effect profile similar to other central nervous system (CNS) depressants. Even though pregabalin is a depressant and anticonvulsant, it can sometimes paradoxically induce seizures, particularly in large overdoses. Adverse drug reactions associated with the use of pregabalin include:
== See also == Lufuradom GYKI-52895, a benzodiazepine which is a dopamine reuptake inhibitor without GABAergic function GYKI-52,466, a benzodiazepine which is an AMPAkine and glutamate antagonist without GABAergic function
=== Screening === Cardiovascular system screening is considered mandatory by the EASL, as MASLD outcomes often result in cardiovascular complications, which can manifest as subclinical atherosclerosis, the cause of most MASLD-related deaths. People with MASLD are at high risk for cardiovascular morbidity and mortality, and "aggressive modification of cardiovascular disease risk factors is warranted in all patients" according to AASLD. The AASLD further recommends that people with a cirrhotic MASH be systematically screened for gastric and esophageal varices and liver cancer. They do not recommend routine liver biopsies and screening for liver cancer for non-cirrhotic people with MASH, but such screening sometimes occurs on a case-by-case basis. Also, people with MASLD may be considered for screening for hepatocellular carcinoma (liver cancer) and gastroesophageal varices. The NICE advises regular screening of people with MASLD for advanced liver fibrosis every three years for adults and every two years for children using the enhanced liver fibrosis (ELF) blood test. Follow-up is recommended for people with obesity and insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR). People with MASH with fibrosis and hypertension merit closer monitoring, as there is a higher risk of disease progression.
== Research == Trazodone may be effective in the treatment of sexual dysfunction, for instance female sexual dysfunction and erectile dysfunction. A 2003 systematic review and meta-analysis found some indication that trazodone may be useful in the treatment of erectile dysfunction. Besides trazodone alone, a combination of trazodone and bupropion (developmental code names and tentative brand names S1P-104, S1P-205, Lorexys, and Orexa) is under development for the treatment of erectile dysfunction and female sexual dysfunction. As of September 2021, it is in phase 2 clinical trials for these indications. It has been in this stage of clinical development since at least February 2015. Trazodone may be useful in the treatment of certain symptoms like sleep disturbances in alcohol withdrawal and recovery. However, reviews have recommended against use of trazodone for alcohol withdrawal due to inadequate evidence. Very limited evidence suggests that trazodone might be useful in the treatment of certain symptoms in cocaine use disorder. Trazodone has been reported to be effective in the treatment of sleep apnea. Cochrane reviews found that trazodone was not effective in the treatment of agitation in dementia. Another Cochrane review found that trazodone might be useful in the treatment of sleep disturbances in dementia. Further systematic reviews have found that trazodone may be effective for behavioral and psychological symptoms in dementias such as frontotemporal dementia and Alzheimer's disease.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.